Barclays Reiterates an 'Overweight' on Onyx Pharmaceuticals (ONXX); Nexavar Growth, CFZ Potential Outweigh Spend
Tweet Send to a Friend
Barclays reiterates an 'Overweight' on Onyx Pharmaceuticals (NASDAQ: ONXX), PT $42.
Barclays analyst says, "With both Nexavar guidance and R&D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "With both Nexavar guidance and R&D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
